Author of

• 16935

  +

  P1.08 - Poster Session with Presenters Present (ID 460)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Surgery
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 16994

    +

    P1.08-059 - Timing of Surgery after Induction Chemoradiation Therapy for Locally Advanced NSCLC (ID 5695)

    14:30 - 14:30  |  Author(s): B. Ozkan
    • Abstract

    Background:
    The timing of surgery after induction chemoradiotherapy (ChRT) for locally Advanced NSCLC is accepted crucial because of technical difficulties, morbidity and related mortality. Although six to eight weeks’ time interval between induction ChRT and surgery is advocated, precise analysis of the optimal waiting time that maximizes oncologic benefits of ChRT has not been established. We aimed to review our results of pulmonary resections performed after induction ChRT and to determine the effects of time interval on postoperative morbidity, mortality and long term survival.
    
    Methods:
    We retrospectively reviewed our records for patients undergoing induction ChRT between 1996 and 2015. Timing of treatment was defined as the difference between the last date of radiotherapy and the date of lung resection. The dose of radiotherapy varied from 45Gy to 66Gy. The patients were divided into two groups, surgery less than eight weeks (Group 1) and more than eight weeks (Group 2) following induction ChRT. Type of resection, postoperative complications, 90-days mortality and long-term survival were analyzed. The impact of surgical timing on outcomes was studied through univariable and multivariable analyses.
    
    Results:
    One hundred and forty-two patients were included into study. The mean time interval between ChRT and surgery was 92.3 days (21-900 days). Sixty-five lung resections were performed less than eight and 77 more than eight weeks. Pulmonary resections were classified as pneumonectomy in 20 patients, lobectomy in 122 patients (of whom, 55 underwent extended resections, chest wall, sleeve etc.). Final pathological examination revealed complete response in 43 (30.3%) of the patients. Major morbidity was observed in 42.2% of the patients [43% (28 of 65pts) in group 1 and 41.5% (32 of 77pts) in group 2, p=0.85]. The overall 90-day mortality rate was 6.3% [7.7% in group 1 and 5.2% in group 2, p=0.54]. The mortality rate after pneumonectomy was 5% (1/20) and 6.5% (8/122) after lobectomy. The 5-year survival rate was 61% vs 47% (p = 0.16). Multivariate analysis showed that timing of surgery after ChRT was not significantly associated with an increased morbidity and mortality that was also not effected by the dose of radiotherapy.
    
    Conclusion:
    These findings indicate that lobectomy or pneumonectomy can be safely performed eight weeks or more after induction ChRT without affecting surgical morbidity and mortality. Pulmonary resection may be performed safely even one year after ChRT.
    
    

• 17398

  +

  P2.01 - Poster Session with Presenters Present (ID 461)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Biology/Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17485

    +

    P2.01-087 - Prognostic Significance of CA IX Overexpression in Stage III NSCLC Patients Received Neoadjuvant Treatment (ID 5174)

    14:30 - 14:30  |  Author(s): B. Ozkan
    • Abstract

    Background:
    The aim of study to investigate prognostic significance of carbonic anhydrase IX gene (CA IX) mRNA expression in stage III NSCLC patients received neoadjuvant treatment
    
    Methods:
    We have studied Carbonic Anhydrase IX (CA IX) mRNA expression at biopsy or surgical pathology tissues of 77 patient with Stage III A/B NSCLC received neoadjuvan treatment. CA IX mRNA expression were evaluated with 50 control .Total RNA were isolated from FFPE tissue from patients while the controls were isolated from the peripheral blood.
    
    Results:
    Median age is 56.Patients histology is 47 pts(61%)squamous cell carcinoma (SCC),30 pts(39%) adenocarcinoma(AC).Neoadjuvan Chemotherapy (NeoAdj CT)was given 45 pts(58,4%);Neoadjuvant chemoradiotherapy(neoAdjCT/RT) was given 32pts(41,6%).Median Neoadjuvan chemotherapy cycles is 3(2-6).Radiotherapy median dose was 60 Gy(45-66).Surgery outcomes is Lobectomy 38pts(49,4%);sleeve lobectomy 11 pts(14,3%),Bilobectomy 6pts(7,8%) Left pnemonectomy (18.2%),right pnemonectomy 8pts(10,4%). Recurrence rate was 39 pts(50,6%).Two year disease free (DFS) and overall survival (OS)was 59,6% and 71,4%. There was OS and DFS difference in favor of Neoadj CT 4-6 cycles versus 2-4 cycles(p=0.009 and p=0.034) There is no statistical difference(p=0,344) for CA IX mRNA expression between SCC and AC. There is no statictical difference for CA IX mRNA expression in Neoadj CT and NeoadjCT/RT groups(p=0.199). There is no statistical difference for OS between ≤Median CA IX versus ≥median groups( 20 events/39 versus 20/38 events p=0,799) There is no statistical difference for DFS between ≤median CA IX versus median groups ≥ (19 events/39 versus 20events /38)
    
    Conclusion:
    There is no any prognostic significance of Carbonic Anhydrase IX expression on DFS and OS in Stage III A/B NSCLC patients received neoadjuvat treatments.